10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

IL13 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP13737b

Specification

IL13 Antibody (C-term) Blocking peptide - Product Information

Primary Accession P35225

IL13 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 3596

Other Names
Interleukin-13, IL-13, IL13, NC30

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13737b was selected from the C-term region of IL13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

IL13 Antibody (C-term) Blocking peptide - Protein Information

Name IL13

Synonyms NC30

Function
Cytokine (PubMed:<a href="http://www.uni

IL13 Antibody (C-term) Blocking peptide - Background

This gene encodes an immunoregulatory cytokine producedprimarily by activated Th2 cells. This cytokine is involved inseveral stages of B-cell maturation and differentiation. Itup-regulates CD23 and MHC class II expression, and promotes IgEisotype switching of B cells. This cytokine down-regulatesmacrophage activity, thereby inhibits the production ofpro-inflammatory cytokines and chemokines. This cytokine is foundto be critical to the pathogenesis of allergen-induced asthma butoperates through mechanisms independent of IgE and eosinophils.This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster onchromosome 5q, with this gene particularly close to IL4. [providedby RefSeq].

IL13 Antibody (C-term) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Shi, X., et al. Anat Rec (Hoboken) 293(9):1470-1476(2010)Beckers, M.M., et al. Eur. J. Intern. Med. 21(4):289-292(2010)Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press :Zhao, M., et al. J. Biomed. Biotechnol. 2010, 931018 (2010) :

prot.org/citations/8096327" target="_blank">8096327, PubMed:8097324). Inhibits inflammatory cytokine production (PubMed:8096327). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). May be critical in regulating inflammatory and immune responses (PubMed:8096327, PubMed:8097324). Positively regulates IL31RA expression in macrophages (By similarity).

Cellular Location
Secreted.

IL13 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides